Table 1 Baseline clinical characteristics in the overall study population.
Characteristics | Non-DM | T2DM with and without SGLT2i | ||
|---|---|---|---|---|
Total | SGLT2i | Non-SGLT2i | ||
Subjects, n | 77,337 | 4,235 | 780 | 3,455 |
Age, years (mean ± SD) | 52 ± 12 | 61 ± 11 | 56 ± 10 | 62 ± 11 |
Sex, n (%) | ||||
Men | 15,657 (20) | 1,486 (35) | 223 (29) | 1,263 (37) |
Women | 61,680 (80) | 2,749 (65) | 557 (71) | 2,192 (63) |
DM duration, n (%) | ||||
< 1 year | NA | 1,130 (27) | 173 (22) | 957 (28) |
1 to 5 years | NA | 1,120 (26) | 220 (28) | 900 (26) |
≥ 5 years | NA | 1,985 (47) | 387 (50) | 1,598 (46) |
DM medications, n (%) | ||||
SGLT2i | NA | 780 (18) | 780 (100) | 0 (0) |
Metformin | NA | 4,077 (96) | 760 (97) | 3317 (96) |
Sulfonylureas | NA | 2,425 (57) | 545 (18) | 1880 (62) |
Glinides | NA | 85 (2) | 15 (2) | 70 (2) |
Thiazolidinediones | NA | 85 (2) | 15 (3) | 70 (2) |
DPP4i | NA | 3,174 (75) | 621 (80) | 2,553 (74) |
α- glucosidase inhibitors | NA | 365 (9) | 85 (11) | 280 (8) |
Distinct OHA class No | ||||
≤ 2 | NA | 1,941 (46) | 98 (13) | 1,843 (53) |
≥ 3 | NA | 2,294 (54) | 682 (87) | 1,612 (47) |
Index year, n (%) | ||||
2014–2016 | 28,890 (37) | 1,162 (27) | 182 (23) | 980 (28) |
2017–2019 | 29,117 (38) | 1,566 (37) | 293 (38) | 1,273 (37) |
2020–2021 | 19,330 (25) | 1,507 (36) | 305 (39) | 1,202 (35) |
Medical history, n (%) | ||||
Hypertension | 13,590 (18) | 2,156 (51) | 375 (48) | 1,781 (52) |
Dyslipidemia | 11,562 (15) | 1,728 (41) | 372 (48) | 1,356 (39) |
Coronary artery disease | 1027 (1) | 143 (3) | 28 (4) | 115 (3) |
Medications, n (%) | ||||
Antithrombotic agents | 6,503 (8) | 1,052 (25) | 186 (24) | 866 (25) |
Statins | 10,392 (13) | 2,362 (56) | 515 (66) | 1,847 (53) |
RAS inhibitors | 10,997 (14) | 1,943 (46) | 367 (47) | 1,576 (46) |
Beta-blockers | 4815 (6) | 511 (12) | 87 (11) | 424 (12) |
Cancer type, n (%) | ||||
Lymphoma | 10,221 (13) | 614 (15) | 97 (12) | 517 (15) |
Breast | 51,045 (66) | 2,096 (49) | 473 (61) | 1,623 (47) |
Genitourinary | 4,580 (6) | 421 (10) | 55 (7) | 366 (11) |
Other cancers | 12,010 (16) | 1,126 (27) | 160 (21) | 966 (28) |
Chemotherapy, n (%) | ||||
AC classes | ||||
Doxorubicin | 74,120 (95) | 3,981 (94) | 752 (96) | 3,229 (93) |
Epirubicin | 2,987 (1) | 248 (5) | 28 (4) | 220 (6) |
Doxorubicin + Epirubicin | 230 (4) | 6 (1) | 0 (0) | 6 (1) |
High-dose ACs | 21,640 (28) | 1,346 (32) | 208 (27) | 1,138 (33) |
Alkylating agents | 3,824 (5) | 140 (3) | 21 (3) | 119 (3) |
Antimicrotubule agents | 34,372 (44) | 1,383 (33) | 306 (39) | 1,077 (31) |
HER2 inhibitors | 11,730 (15) | 474 (11) | 91 (12) | 383 (11) |
VEGF-targeting agents | 2,892 (4) | 224 (5) | 27 (3) | 197 (6) |
